[177Lu]Lu-FAP-2286与[161Tb]Tb-FAP-2286在PDAC小鼠模型中的疗效头对头比较
该临床前研究在FAP表达细胞、患者肿瘤样本及PDAC小鼠模型中头对头比较了[177Lu]Lu-FAP-2286与[161Tb]Tb-FAP-2286的体外摄取、体内生物分布与疗效。结果显示两种药物体外摄取无差异,单药4×40 MBq/500 pmol均未带来生存获益,而先[177Lu]后[161Tb]的序贯治疗组出现适度生存延长;基于患者肿瘤样本的剂量学计算提示[161Tb]Tb-FAP-2286即使结合较低也可实现更高的肿瘤吸收剂量。
要点
- 体外细胞模型中两种放射性药物的摄取无差异。
- 单药4×40 MBq/500 pmol方案在小鼠中未见生存获益。
- 先[177Lu]后[161Tb]的序贯方案观察到适度生存延长。
核心结论
- 在所用PDAC小鼠模型中FAP-TRT疗效有限,可能源于肿瘤对放射性药物摄取有限,妨碍了判断任一放射性核素的潜在优势。
- 先给予[177Lu]Lu-FAP-2286、后给予[161Tb]Tb-FAP-2286的序贯治疗组观察到适度疗效反应。
研究设计与样本
- 临床前研究:FAP-2286分别标记Lu-177与Tb-161,在FAP表达细胞中行体外表征,并用患者肿瘤样本行离体研究。
- 体内研究采用临床代表性PDAC小鼠模型,注射5 MBq/500 pmol后1、4、24、48小时行生物分布。
- 治疗分组为4×40 MBq/500 pmol [177Lu]Lu-FAP-2286、4×40 MBq/500 pmol [161Tb]Tb-FAP-2286,以及两种药物交替的2×40 MBq/500 pmol序贯方案。
主要发现
- 细胞模型中[177Lu]Lu-FAP-2286与[161Tb]Tb-FAP-2286摄取无差异。
- 体内研究未显示4×40 MBq/500 pmol [177Lu]Lu-FAP-2286或[161Tb]Tb-FAP-2286的生存获益。
- Kaplan-Meier分析显示先接受[177Lu]Lu-FAP-2286后接受[161Tb]Tb-FAP-2286的小鼠生存适度延长。
- 基于患者肿瘤样本放射自显影的剂量学计算显示,即使结合较低,[161Tb]Tb-FAP-2286仍可实现更高的肿瘤吸收剂量。
临床怎么用
- 该临床前结果尚不能支持在PDAC中优先选用[161Tb]Tb-FAP-2286或[177Lu]Lu-FAP-2286单药方案。
- 先[177Lu]后[161Tb]的序贯给药策略值得在进一步研究中验证。
局限性
- 作者指出所用PDAC小鼠模型中肿瘤对放射性药物摄取有限,限制了疗效评估及判断任一放射性核素的潜在优势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Terbium-161 (Tb-161) emits internal conversion and Auger electrons, in addition to beta-minus radiation, which might be of added benefit for targeted radionuclide therapy (TRT) compared to Lutetium-177 (Lu-177). We extensively compared Lu-177 and Tb-161 for fibroblast activation protein (FAP)- TRT in a preclinical setting. To study this, FAP-2286 was labeled with Lu-177 and Tb-161 and characterized in vitro on FAP-expressing cells and ex vivo using patient tumor samples. Moreover, in vivo studies (i.e. biodistribution and efficacy) were performed using a clinically representative pancreatic ductal adenocarcinoma (PDAC) mouse model. Biodistribution was performed 1, 4, 24, and 48 h post injection of 5 MBq/500 pmol [177Lu]Lu-FAP-2286 or [161Tb]Tb-FAP-2286. Subsequently, animals were treated with 4 × 40 MBq/500 pmol [177Lu]Lu-FAP-2286 or [161Tb]Tb-FAP-2286 and with alternating doses of 2 × 40 MBq/500 pmol of each radiopharmaceutical. RESULTS: No difference in [177Lu]Lu-FAP-2286 and [161Tb]Tb-FAP-2286 uptake was observed in the cell models. In vivo studies did not show a survival benefit of 4 × 40 MBq/500 pmol [177Lu]Lu-FAP-2286 or [161Tb]Tb-FAP-2286, while Kaplan-Meier analyses demonstrated a modest prolonged survival after tandem therapy in mice that first received [177Lu]Lu-FAP-2286 followed by [161Tb]Tb-FAP-2286. Dosimetry calculations based on autoradiography studies on patient tumor samples showed that even with lower binding, a higher absorbed dose to the tumor can be accomplished with [161Tb]Tb-FAP-2286. CONCLUSIONS: In our in vitro and in vivo studies, [177Lu]Lu-FAP-2286 and [161Tb]Tb-FAP-2286 demonstrated similar behavior. In the applied PDAC mouse model, FAP-TRT showed limited therapeutic efficacy, most likely due to the limited radiopharmaceutical uptake observed in the tumors. This hampered determination of a potential benefit of either radioisotope for FAP-TRT. Of note, a modest response was observed in the tandem therapy group that first received [177Lu]Lu-FAP-2286, followed by [161Tb]Tb-FAP-2286.
引用
- van der Heide CD, Ntihabose CM, Konijnenberg M, et al. Head-to-head comparison of [177Lu]Lu-FAP-2286 and [161Tb]Tb-FAP-2286 efficacy in a PDAC mouse model. EJNMMI Res. 2026. PMID: 41511675. doi:10.1186/s13550-026-01372-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。